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ORIGINAL ARTICLE
Revealing the complex genetic architecture of
obsessive–compulsive disorder using meta-analysis
International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics
Association Studies (OCGAS)1
Two obsessive–compulsive disorder (OCD) genome-wide association studies (GWASs) have been published by independent OCD
consortia, the International Obsessive-Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and the OCD
Collaborative Genetics Association Study (OCGAS), but many of the top-ranked signals were supported in only one study. We
therefore conducted a meta-analysis from the two consortia, investigating a total of 2688 individuals of European ancestry with
OCD and 7037 genomically matched controls. No single-nucleotide polymorphisms (SNPs) reached genome-wide significance.
However, in comparison with the two individual GWASs, the distribution of P-values shifted toward significance. The top haplotypic
blocks were tagged with rs4733767 (P= 7.1 × 10− 7; odds ratio (OR) = 1.21; confidence interval (CI): 1.12–1.31, CASC8/CASC11),
rs1030757 (P= 1.1 × 10− 6; OR = 1.18; CI: 1.10–1.26, GRID2) and rs12504244 (P= 1.6 × 10− 6; OR = 1.18; CI: 1.11–1.27, KIT). Variants
located in or near the genes ASB13, RSPO4, DLGAP1, PTPRD, GRIK2, FAIM2 and CDH20, identified in linkage peaks and the original
GWASs, were among the top signals. Polygenic risk scores for each individual study predicted case–control status in the other by
explaining 0.9% (P= 0.003) and 0.3% (P= 0.0009) of the phenotypic variance in OCGAS and the European IOCDF-GC target samples,
respectively. The common SNP heritability in the combined OCGAS and IOCDF-GC sample was estimated to be 0.28
(s.e. = 0.04). Strikingly, ∼ 65% of the SNP-based heritability in the OCGAS sample was accounted for by SNPs with minor allele
frequencies of ⩾ 40%. This joint analysis constituting the largest single OCD genome-wide study to date represents a major
integrative step in elucidating the genetic causes of OCD.
Molecular Psychiatry (2018) 23, 1181–1188; doi:10.1038/mp.2017.154; published online 1 August 2017
INTRODUCTION
Obsessive–compulsive disorder (OCD) is a psychiatric condition
characterized by persistent, intrusive thoughts and urges (obses-
sions) and repetitive, intentional behaviors (compulsions), typi-
cally, but not always, performed to reduce anxiety caused by
obsessions.1 The estimated lifetime prevalence of OCD is 1–3%,
based on national surveys.2 Individuals with OCD experience a
chronic or episodic course with exacerbations that can substan-
tially impair social and occupational functioning.1
Since the early twentieth century, clinicians have suspected that
heredity plays an important role in susceptibility to OCD. Consistent
with this, several family studies have found a substantially greater
prevalence of OCD (∼10-fold increase) in the first-degree relatives
of probands, compared with relatives of controls.3–6 Family studies
of OCD in child and adolescent probands report even greater
differences in the risk of OCD in relatives of cases compared with
controls,7,8 consistent with previous reports of increased familial
loading with an early age at onset.3,4
The few existing studies that have examined twin concordance
rates for OCD are insufficient in size to allow for accurate
heritability estimates.9 However, population-based twin studies
estimate the heritability of dimensional measures of obsessive–
compulsive symptoms (OCS) to be 40–50%, with a similar
contribution from nonshared environment and no significant
contribution from shared environment.10–14 More recently, direct
interrogation of the genome using genome-wide complex trait
analysis (GCTA) on data from the International OCD Foundation
Genetics Consortium (IOCDF-GC) genome-wide association study
(GWAS) provided heritability estimates of 0.37 (s.e. = 0.07,
P= 1.5 × 10− 07) for OCD. In the same sample, the estimate of
heritability for childhood-onset OCD (symptoms before the age of
17 years15) was 0.43 (s.e. = 0.10, P= 1× 10− 05). Partitioning by
minor allele frequency (MAF) suggested that the vast majority of
the heritability was accounted for by single-nucleotide poly-
morphisms (SNPs) with MAF 40.30; little heritability was
accounted for by SNPs with a MAF of o5%.15
To date, eight whole-genome studies of OCD or OCS have been
published, including five linkage studies,16–22 two GWASs of
OCD23,24 and one GWAS of OCS.25 The five linkage studies
identified several chromosomal regions with suggestive evidence
for linkage,16–20 although there was little overlap between them
and only one (1p36) met criteria for statistical significance for
linkage.16 Consistent with sample size expectations for highly
polygenic traits, no individual susceptibility variants have yet been
identified for OCD using these methods.
The two published GWASs of OCD were conducted by indepen-
dent OCD consortia: the IOCDF-GC24 and the OCD Collaborative
Genetics Association Study (OCGAS).23 The IOCDF-GC published
the first OCD GWAS, comprising 1465 cases and 5557 ancestry-
matched controls, as well as 400 complete trios, from 22 sites
worldwide.26 The top signal from the combined trio–case–control
sample was rs297941 on chromosome 19p13.2, near FAIM2
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(P= 4.99 × 10− 7). Although no SNPs were found to be associated
with OCD at a genome-wide significance level, a significant
enrichment of methylation quantitative trait loci (Po0.001) and
frontal lobe expression quantitative trait loci (eQTLs; P= 0.001)
were observed within the top-ranked SNPs, providing evidence,
consistent with other disease reports,27,28 that biologically
relevant associations are present within subthreshold GWAS
results. The OCGAS reported a second GWAS, conducted by six
research centers in the United States.23 In this study, 1065 families
(containing 1406 patients with OCD), combined with population-
based control samples (resulting in a total sample of 5061
individuals), were studied. The smallest P-value (P= 4.13 × 10− 7)
was detected for a SNP on chromosome 9p23, in close proximity
to the protein tyrosine phosphate receptor D (PTPRD) gene. The
second smallest P-value was 1.76 × 10− 6 near the cadherin type 9
and 10 (CDH9 and CDH10) genes on chromosome 5p15.
A third GWAS, this one examining quantitative OCS, was
conducted in 6931 individuals from the Netherlands Twin
Registry.25 This study identified one gene that met criteria for
genome-wide significance, the myocyte enhancer factor 2B
neighbor (MEF2BNB) (P= 2.56 × 10− 8), on chromosome 19p13.
The total SNP-based heritability for OCS in this sample was 0.14
(s.e. = 0.05, P= 0.003), and the polygenic risk score (PRS) derived
from the IOCDF-GC GWAS was significantly associated with OCS,
explaining 0.2% of the variance.
As is evident from the data above, although multiple regions of
interest have been reported, there is currently little convergence
of results to identify OCD susceptibility variants. This is likely
because of genetic and phenotypic heterogeneity, and insufficient
sample sizes. Thus, a logical next step is to use comparable data
sets in combined analyses to increase power. Here, we report
findings from combined analyses of the IOCDF-GC and OCGAS
GWAS data aimed at further exploring the genetic underpinnings
of OCD. We first used the genotypes of these two studies, after
imputation to a common reference, to conduct a joint GWAS. We
then used each individual study as a discovery sample for PRS
analysis and predicted case–control status in the alternate data set
to investigate the amount of phenotypic variation explained by
the respective PRS. To replicate the finding that SNPs with high
MAF account for the majority of the heritability in OCD, we next
computed the common variation heritability of the OCGAS sample
using GCTA and performed the same partitioning, as previously
reported.15 Finally, we used linkage disequilibrium (LD) score




For these analyses we used only individuals of European ancestry from the
original GWAS samples, yielding 1429 cases, 5089 controls and 285 trios
from IOCDF-GC and 344 cases and 1033 controls and 630 trios from OCGAS
(Supplementary Table S1), after the addition of screened controls from the
Genomic Psychiatry Cohort,30 matched to the OCGAS cases. All cases met
DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition),
criteria for OCD.1 Controls from the IOCDF-GC GWAS were unscreened.
Additional information on the IOCDF-GC and OCGAS samples and
methods has been previously published.23,26 This work was approved by
the relevant institutional review boards at all participating sites, and all
participants provided written informed consent.
GWAS analyses
We imputed genotype-level data from the IOCDF-GC (except the Dutch
samples that were imputed separately, see below), OCGAS and Genomic
Psychiatry Cohort samples using IMPUTE2 (ref. 31) and reference
haplotypes from the 1000 Genomes Project (Phase I integrated variant
set release); NCBI build 37 (hg19) was constructed with SHAPEIT2.32 We
assessed genetic relatedness between samples through identity-by-
descent estimation between all sample pairs using PLINK33 and retained
only one member of each pair of samples with pi_hat 40.2. Samples were
excluded if they had a call rate of o0.98, an absolute value of F_HET
40.20 or absence or unambiguous correct genotypic sex. SNPs were
excluded from pre-imputation data set if the call rate was o0.98, MAF
o0.01,
case–control differential missingness was 40.02 or the P-value of Hardy–
Weinberg equilibrium was o1.0 × 10− 6 for controls and o1.0 × 10− 10 for
cases. After imputation, SNPs were excluded if IMPUTE2 info was o0.6,
IMPUTE2 certainty was o0.9 or MAF was o0.01. We assessed population
structure using multidimensional scaling and, as previously observed,24
samples of Ashkenazi Jewish or Afrikaans (South African) ethnicity
clustered as separate groups (Supplementary Figures S1–S5). We
conducted separate association analyses for each case–control subpopula-
tion (IOCDF-GC European (IOEU), IOCDF-GC Ashkenazi Jewish (IOAJ),
IOCDF-GC South African (IOSA), OCGAS case–control (OCCC)) and trio
sample (IOCDF-GC trios (IOTR) and OCGAS trios (OCTR); as probands versus
pseudo-controls). We defined ‘pseudo-controls’ as the non-transmitted
haplotype pairs from parents to affected offspring in the trio samples.
Because of more stringent data sharing restrictions for Dutch cases,
imputation and summary statistics for the Dutch cases and population-
matched controls (IODU) were calculated separately by the site
investigators following the same imputation and quality control (QC)
procedures. We then performed meta-analysis using the summary statistics
of all case–control subpopulations (including IODU) and trio samples using
METAL34 with the inverse variance method on SNPs that passed QC in at
least 500 cases and 500 controls. Results were visualized with Assocplots.35
The top loci of meta-analysis were defined by the regions of LD pruned
independent top SNPs passing predefined P-value threshold (r2o0.2,
500 kb window, clump function in PLINK) and their tagged SNPs (r240.2,
1000 kb window, show-tags function in PLINK) using 1KG samples of
European independent founders (EUR, TSI and GBR, phase 1) as the
reference panel.
PRS analysis
We conducted PRS analyses using PLINK, as previously described,36 to test
whether multiple variants of small effect jointly contribute to OCD. PRSs for
subsets of the IOCDF-GC sample (IOEU) and the OCGAS sample (OCTR)
(target samples) were calculated based on the SNP effect size estimated
from the discovery samples, the OCGAS and European ancestry IOCDF-GC
samples (excluding IOAJ), respectively. Imputed SNPs with high quality
(IMPUTE2 info 40.95, MAF 40.05) and GWAS P-values passing
predetermined significance thresholds (Po0.0001, 0.001, 0.01, 0.1, 0.2,
0.3, 0.4 and 0.5) in the discovery samples were extracted along with their
risk alleles and odds ratios (ORs), and then LD pruned within 500 kb
window at r240.2 (clump function in PLINK) using 1KG samples of
European independent founders (EUR, TSI and GBR, phase 1) as the
reference panel.
For each significance threshold, a quantitative aggregate risk score was
calculated for each individual in the target sample IOEU and OCTR, defined
as the sum of the number of risk alleles present at each locus weighted by
the log of the OR for that locus estimated from the discovery sample. We
examined the relationship between aggregate risk score and case–control
status in the target samples, IOEU and OCTR, at each significance
threshold, using logistic regression controlling for population stratification.
We then estimated the percentage of phenotypic variance explained by
the aggregate risk score (Nagelkerke’s pseudo-R2).
Heritability and genetic correlations
Genetic complex trait analysis. We used GCTA v1.24 (http://cnsgenomics.
com/software/gcta/) to estimate the proportion of phenotypic variance
explained by directly genotyped and imputed SNPs in the OCGAS sample,
as has previously been done in the IOCDF-GC sample.15 Because of the
sensitivity of GCTA to low-quality SNPs and remotely related samples, we
conducted more stringent QC for these analyses by removing SNPs with
Hardy–Weinberg equilibrium Po0.05 and platform effects with Po0.01
(detected by GWAS comparison of platforms among population-matched
controls) and removing one member of each sample pair with
pi_hat40.05. For directly genotyped and imputed SNPs respectively, this
resulted in 487 459 directly genotyped and 5 843 119 imputed SNPs on
999 cases and 1064 controls. After QC, we used the GCTA software to
generate a genetic relationship matrix (GRM) file that included identity-by-
descent relationships calculated from genotype data. Genomic restricted
maximum likelihood (GREML) analysis was conducted using the respective
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GRM estimated from all the SNPs and 20 principal component quantitative
covariates. In order to account for the oversampling of cases, we used the
OCD population prevalence (2.5%) to transform the estimate of variance
explained to the liability scale. Finally, we estimated the chromosome-
specific heritability and heritability partitioned by MAF for five MAF bins
(0.01–0.1, 0.1–0.2, 0.2–0.3, 0.3–0.4 and 0.4–0.5).
We then combined the two largest European IOCDF-GC and OCGAS data
sets (not including trios, IOAJ, IOSA or Dutch), and performed a second
round of QC to remove any samples that fell outside the European genetic
cluster, and one sample of any pair with a pi-hat 40.05, resulting in 1323
cases and 4938 controls. At the SNP level, we filtered the imputed SNPs
based on the imputation info quality metric (info40.6), certainty (o80%)
and MAF (o0.05) that resulted in 5 235 858 SNPs. A prevalence of 2.5%
and 20 principal components were used for the GREML analysis.
LD score regression analysis. We applied the LD score regression (LDSC)
method29 to 1 159 580 imputed and directly genotyped SNPs (that
overlapped with a panel of high confidence HapMap3 SNPs) measured
on all 9725 (2688 cases and 7037 controls) individuals included in the OCD
meta-analysis. Regression weights were calculated using the HapMap
European reference sample provided by Bulik-Sullivan et al.29 To transform
from the observed heritability scale to the liability scale we used a
population prevalence of 2.5%. Using LDSC, we calculated heritability,
checked for residual population stratification (based on the LDSC




After data cleaning to remove samples falling outside the
European genetic cluster, we had a total sample size of 2688
OCD cases and 7037 gnomically matched controls, comprising
seven subsamples (Supplementary Table S1) that were analyzed
individually and then combined by meta-analysis to provide
overall P-values on 8 693 187 autosomal SNPs. We generated
quantile–quantile plots of the observed versus expected log(P)
values under the null hypothesis and calculated the genomic
control lambda for the final sample. We observed no evidence for
significant residual stratification effects (Supplementary Figure S6;
λ= 1.028; λ1000 = 1.007). In addition, the LDSC analysis demon-
strated no evidence of residual population stratification (LDSC
intercept = 1.0005; s.e. = 0.0068).
No SNP exceeded the genome-wide threshold for significance
(Figure 1 and Table 1). A total of 130 SNPs (Supplementary Table
S2) from 29 LD independent loci (Table 1) were observed with
Po1.0 × 10− 5. The SNP with the lowest P-value was rs4733767
(P= 7.1 × 10− 7; OR = 1.21; confidence interval (CI):1.12–1.31) that
tagged a haplotypic block of 53.7 kb (chr8: 128 568 359–
128 622 083) on chromosome 8q24.21 and is 87.2 kb 5′ to CASC8
(Cancer Susceptibility Candidate 8, also known as LOC727677)
(Table 1, Supplementary Table S2 and Supplementary Figure S7).
The SNP with the second lowest P-value, rs1030757
(P= 1.1 × 10− 6; OR = 1.18; CI: 1.10–1.26), on chromosome 4q22.1
tagged the second best haplotype block (chr4: 93 479 275–
94 230 511; 751.2 kb; Supplementary Figure S8) that lies wholly
within GRID2 (Glutamate Ionotropic Receptor Delta Type Subunit 2).
Within this haplotype there were SNPs with heterogeneity
P-values of o0.05; we conducted random-effects meta-analysis
using PLINK and the findings were different. We identified that the
heterogeneity came from the isolate subpopulation South African.
Excluding this sample (post hoc) from the meta analysis, the
Figure 1. Manhattan plot of genotyped and imputed single-nucleotide polymorphisms (SNPs) for 2688 obsessive–compulsive disorder (OCD)
cases and 7031 controls from the International Obsessive-Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC), OCD
Collaborative Genetics Association Study (OCGAS) and Genomic Psychiatry Cohort (GPC) consortia. Black line near the top of the figure
indicates the genome-wide significance threshold of P= 5× 10− 8.
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association with OCD for the SNPs with heterogeneity became
more significant (for example, rs7683744: P= 8.0 × 10− 7; OR =
0.84). The SNP with the third lowest P-value, rs12504244
(P= 1.6 × 10− 6; OR = 1.18; CI: 1.11–1.27), on chromosome 4q12
tagged the third best haplotypic block (chr4: 55 476 381–
55 580 596; 104.2 kb; Supplementary Figure S9) that overlies the
promoter and much of the gene body of KIT (KIT Proto-Oncogene
Receptor Tyrosine Kinase).
PRS analysis
We used SNP effect sizes derived from the individual OCGAS and
IOCDF-GC meta-analyses to calculate PRS and predict OCD status
in individuals of European ancestry from the IOCDF-GC sample
(IOEU) and in trios of European ancestry from the OCGAS sample
(OCTR), respectively. As shown in Figure 2 and Supplementary
Table S3, the PRS derived from meta-analysis of the European
IOCDF-GC samples (excluding the IOAJ samples to avoid hetero-
geneity in the discovery sample) reasonably predicted case–
control status in the OCGAS trio target sample (P= 0.003),
explaining ∼ 0.9% of the phenotypic variance. Conversely, risk
scores derived using the OCGAS as a discovery sample explained
0.3% of the phenotypic variance in the IOEU samples (P= 0.0009).
Heritability analyses
GCTA-based heritability in the OCGAS sample alone (999 cases
and 1064 controls; Table 2) was 0.25 (s.e. = 0.11, P= 0.0096). The
GCTA heritability estimate of OCD in the combined OCGAS and
IOCDF-GC European sample was also 0.25 (s.e. = 0.05; P= 0.0096).
LDSC analysis yielded a heritability estimate of 0.28 (s.e. = 0.04) for
the combined OCD sample (Table 2). When the sample was then
split into its constituent parts (OCGAS and IOCDF-GC), we
observed a significant genetic correlation between the two
(rg = 0.83; s.e. = 0.28; P= 0.003).
In parallel with the univariate and bivariate analyses, we
partitioned heritability by allele frequency in the OCGAS sample
using five MAF bins as 0.01–0.1, 0.1–0.2, 0.2–0.3, 0.3–0.4 and
0.4–0.5 in the GRMEL joint analysis; results are presented in
Supplementary Table S4. As has been previously reported for the
IOCDF-GC sample,15 the largest proportion of heritability was
observed in the highest frequency allele bins (MAF 40.4).
Table 1. LD-independent genomic regions with Po × 10− 5 in the combined OCD genome-wide association study (GWAS)
SNP Chr BP A1/A2 A1 FRQ INFO Odd ratio
(95% CI)
P LD block (hg19) Genes
rs4733767 8 128 581 578 A/G 0.274 0.867 1.21 (1.12–1.31) 7.1E− 07 128568359–128622083
rs1030757 4 93 697 153 C/A 0.488 0.979 1.18 (1.10–1.26) 1.1E− 06 93479275–94230511 GRID2
rs12504244 4 55 485 188 G/C 0.393 0.974 1.18 (1.11–1.27) 1.6E− 06 55476381–55580596 KIT
rs13141765 4 6 243 646 C/T 0.393 0.713 1.31 (1.17–1.46) 1.9E− 06 6239015–6249840 LOC285484






rs72781967 10 5 622 426 C/T 0.344 0.995 1.18 (1.10–1.27) 2.4E− 06 5607539–5659916





rs117310268 18 19 675 267 T/C 0.038 0.780 1.57 (1.30–1.89) 3.3E− 06 19505213–19683750
rs5019028 4 94 222 825 G/T 0.279 0.995 1.19 (1.11–1.28) 3.4E− 06 93665778–94232270 GRID2
rs72783425 16 14 148 431 A/C 0.053 0.960 1.40 (1.22–1.62) 3.5E− 06 13982844–14318912 ERCC4, LOC101927311,
LOC101927348, MKL2
rs56343802 2 139 823 241 T/A 0.281 0.999 1.19 (1.10–1.27) 4.0E− 06 139821308–139882668
rs909701 22 44 973 368 G/C 0.500 0.999 1.17 (1.09–1.25) 4.1E− 06 44971548–44988209 LINC00207, LINC00229
rs9952159 18 3 660 801 T/C 0.220 1.026 1.20 (1.11–1.30) 4.2E− 06 3638103–3710355 DLGAP1
rs77885126 18 58 420 429 C/T 0.015 0.932 1.83 (1.41–2.36) 4.4E− 06 58250265–59372219 CDH20
rs10773765 12 130 767 334 T/C 0.252 0.907 1.20 (1.11–1.30) 5.2E− 06 130739141–130857497 PIWIL1
rs9544927 13 79 505 864 G/A 0.208 0.996 0.82 (0.76–0.90) 5.7E− 06 79496764–79551012
rs28599745 1 153 396 665 A/G 0.160 0.650 0.70 (0.59–0.81) 6.0E− 06 153349194–153396665 S100A7A, S100A7L2, S100A8,
S100A9, S100A12
rs1652783 8 73 279 728 G/A 0.225 0.764 1.31 (1.16–1.47) 6.1E− 06 73279414–73312929
rs190543171 5 15 840 912 T/C 0.012 0.787 2.32 (1.61–3.35) 6.1E− 06 15726922–16139424 FBXL7, MARCH11
rs56025909 20 955 893 T/C 0.032 0.960 1.51 (1.26–1.81) 7.2E− 06 931170–991579 RSPO4
rs3097331 19 34 648 956 C/T 0.368 1.000 0.85 (0.80–0.92) 7.5E− 06 34632485–34727202 KIAA0355, LSM14A
rs138445568 3 143 922 936 T/A 0.013 0.630 2.53 (1.68–3.80) 7.7E− 06 142971745–144868438 C3orf58, SLC9A9, SLC9A9-AS1
rs139286049 9 20 688 387 G/A 0.019 0.760 1.82 (1.40–2.37) 7.8E− 06 20688387–21100533 FOCAD, IFNB1,MIR491, PTPLAD2
rs146238482 9 20 856 226 C/G 0.010 0.823 2.68 (1.74–4.13) 8.1E− 06 20836624–21016372 FOCAD, PTPLAD2
rs35894340 18 54 307 062 G/A 0.252 0.948 1.19 (1.10–1.29) 8.4E− 06 54246712–54518866 TXNL1, WDR7
rs149952789 7 12 716 170 T/A 0.010 0.603 3.33 (1.96–5.68) 9.6E− 06 12716170–12716170 ARL4A
rs4444795 4 93 355 172 T/C 0.183 0.912 1.22 (1.12–1.33) 9.7E− 06 93195208–94077524 GRID2
rs75740353 2 242 741 686 A/G 0.103 0.869 0.65 (0.54–0.79) 9.7E− 06 242685298–242764651 D2HGDH, GAL3ST2, ING5, NEU4
rs116969557 13 77 337 736 A/G 0.016 0.957 1.77 (1.38–2.29) 9.9E− 06 77082597–77566923 BTF3P11, CLN5, FBXL3, IRG1, KCTD12
Abbreviations: A1, minor allele; A1 FRQ, frequency of A1 allele; A2, major allele; BP, chromosomal position, in base pairs; Chr, chromosome; CI, confidence
interval; INFO, INFO score; LD, linkage disequilibrium; OCD, obsessive–compulsive disorder; SNP, single-nucleotide polymorphism LD block indicates tagged
region by the index SNP at r240.2; Genes indicate genes and their 20 kb flanking regions on each side overlapped with the LD block.
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DISCUSSION
We report the results of a meta-analysis of GWAS from the two
published genome-wide association studies of OCD, with a sample
of 2688 individuals with OCD that include both family-based and
singleton cases, and 7037 controls. PRS and LDSC analyses confirm
that the two samples share genetic risk factors for OCD, and are
thus appropriate for combined GWAS analyses. With LDSC we
observed a strong genetic correlation between the IOCDF-GC and
OCGAS samples (rg = 0.83, s.e. = 0.28; P= 0.003). PRS derived from
each sample significantly predicted case–control status in the
other sample. Although the phenotypic variance explained was
relatively small (R2 = 0.9% for the OCGAS trios and 0.3% for the
IOCDF-GC European cases and controls), they are comparable to
those found for schizophrenia, using similar discovery sample
sizes37 (PGC2 SCZ GWAS, 2014).
Using GCTA, the heritability tagged by the SNPs in the OCGAS
sample was slightly lower (25%) than previously observed for the
IOCDF-GC sample (32%).15 The ascertainment strategies differed in
IOCDF-GC and OCGAS studies, with the former recruiting
individuals, and the latter primarily families (trios) that may
underestimate the heritability tagged by SNPs, as the polygenic
load in family members of affected individuals is elevated in
comparison with controls.38 Joint heritability analyses of the two
samples, using GCTA and LDSC, resulted in similar estimates (0.25
and 0.28, respectively), suggesting that the common variation
heritability of OCD is between 25 and 30% (that is, ⩾ 50% of the
total heritability than estimated by twin studies.
We also examined the allele frequency distribution of the
common variation heritability of OCD. Although the confidence
intervals of each allele frequency bin are large because of the
limited sample sizes, the majority of the heritability (~65%) was
accounted for by SNPs with high MAF (for example, 440%) in
both the OCGAS sample alone and combined sample
(Supplementary Table S4).
Although there were no genome-wide significant findings, the
53.7 kb (chr8: 128 568 359–128 622 083) haplotype block encom-
passing the top SNP, rs4733767 (Supplementary Figure S7),
contains 25 H3K27Ac peaks in the ENCODE/ROADMAP data,
suggesting it has regulatory potential,39 although the current
release of the Genotype-Tissue Expression project (GTEx Release
V6 (dbGaP Accession phs000424.v6.p1))40 has no eQTLs in the
block. The closest genes on either side of rs4733767 (CASC8 and
CASC11) are long noncoding RNAs that are thought as a class to
have regulatory functions.41 Both are only expressed at low levels
in the brain in the GTEx database. The potential transcriptional
consequences of genomic risk for OCD in this region are unclear,
at present.
The second best haplotypic block (chr4: 93 479 275–94 230 511)
lies entirely within GRID2, a gene expressing a subunit of an
ionotropic glutamate receptor, and contains ∼ 300 H3K27Ac
peaks. The region between ~ 94 120 000 and 94 230 000 kb
contains multiple SNPs that regulate GRID2 in both brain (www.
BRAINEAC.org, intralobular white matter (n= 131))42 and testis
(GTEx Release V6). In the latter, two of these SNPs overlap with
those observed in this study (rs7684707 and rs5019028), and the
OCD risk allele is predicted to increase expression. These eQTLs
were not detected in brain in the GTEx study, most likely as a
consequence of small sample size. GRID2 is highly expressed in
the cerebellum, but is also expressed in other regions of the brain
throughout the lifespan (www.BrainSpan.org), with detectable
expression in the caudate, putamen, nucleus accumbens and the
anterior cingulate cortex, all regions that have been implicated in
OCD,43 and is part of the glutamatergic signaling system that is
thought to be important in OCD.44 Deletions of portions of GRID2
in humans are responsible for spinocerebellar ataxia, autosomal
recessive 18 (SCAR18; http://omim.org/entry/602368) that are



















































































Figure 2. Polygenic risk score (PRS) analysis in obsessive–compulsive
disorder (OCD). The variance explained in two target samples (OCTR,
consisting of 630 cases and 630 pseudo-controls; IOEU, consisting of
1032 cases and 4100 controls) is based on risk scores derived from
an aggregated sum of weighted single-nucleotide polymorphism
(SNP) risk allele effect sizes estimated from the discovery samples
(IOCDF-GC without IOAJ, consisting of 1623 cases and 5113 controls;
OCGAS, consisting of 974 cases and 663 controls) at eight
significance thresholds. The numbers of SNPs used at each
significance thresholds for PRS were listed on the top of the
corresponding bars. The y axis indicates Nagelkerke’s pseudo-R2.
IOCDF-GC, International Obsessive-Compulsive Disorder Foundation
Genetics Collaborative; OCGAS, OCD Collaborative Genetics
Association Study.
Table 2. Heritability estimates for OCD in the IOCDF-GC and OCGAS samples
Sample characteristics Method Cases Controls Number of SNPs Reference V(g)/V(p)_Liability (s.e.)
IOCDF-GC case–control GCTA 1061 4236 7 657 106 Davis et al.15
OCGAS case–control and trio controls GCTA 999 1064 5 843 119 This study
OCGAS and IOCDF-GC cases–control EU only GCTA 1323 4398 5 235 858 This study
OCGAS and IOCDF-GC case–control and pseudo-control LDSC 2936 7279 1 159 580 This study
Abbreviations: GCTA, genome-wide complex trait analysis; IOCDF-GC, International Obsessive-Compulsive Disorder Foundation Genetics Collaborative; LDSC,
linkage disequilibrium score regression; OCD, obsessive–compulsive disorder; OCGAS, OCD Collaborative Genetics Association Study; SNP, single-nucleotide
polymorphism.
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These observations suggest that lower GRID2, particularly in the
cerebellum causes ataxia, whereas higher GRID2, especially in the
non-cerebellar brain, may increase risk for OCD.
The third best haplotypic block observed contains the promoter
and much of the gene body of KIT. No eQTLs for KIT are found in
GTEx (V6), but the haplotypic block is likely to regulate the gene,
as it contains 47.7 kb 5′ to the transcription start site, and has 76
H3K27Ac peaks. KIT is expressed in multiple brain regions
(BrainSpan and GTEx) and across the human lifespan, with highest
expression during fetal development (BrainSpan). Allelic variants
of KIT in humans have been observed in individuals with
piebaldism, various leukemias and gastrointestinal stromal tumors
(http://omim.org/entry/164920?search = kit&highlight = kit). Of
note, both KIT and GRID2 are regulated by transforming growth
factor-β1 in rodents.46–48
Comparison of findings in prior linkage or GWAS studies of OCD
Of the signals with P-values of o1 × 10− 5 in this meta-analysis,
two were in genomic regions that have been previously identified
in genome-wide linkage studies. These include 7 SNPs on
chromosome 10p15,18 all of which are eQTLs of ASB13 (ankyrin
repeat and SOCS box containing 13), in Epstein–Barr virus-
transformed lymphocytes, and predict high expression (GTEx
Release V6). A 60.4 kb haplotypic block was seen in a linkage peak
on 20p13 (ref.16) that encompasses the gene for RSPO4 and part of
its promoter. The block contains SNPs that are eQTLs for RSPO4 in
about a dozen tissues and an eQTL for SRXN1 in thyroid. As
mentioned above, the number of brain samples in the V6 release
is ⩽ 100, limiting the power to detect brain eQTLs. Overall, most of
the eQTLs being detected at the present sample sizes in the GTEx
project affect multiple tissues, and hence it is plausible that these
SNPs may also be regulating the same genes in brain. Final
determination of this will require more data.
Of the signals identified in the three prior OCD GWASs,23–25
SNPs within DLGAP1, which was identified in the IOCDF-GC GWAS,
represented the signal most strongly supported in this meta-
analysis (best was rs9952159, P= 4.2 × 10− 6, OR = 1.20). Among
the other genes of interest, signals in or near PTPRD, which was
previously identified in the OCGAS GWAS (P= 2.4 × 10− 4, OR =
1.45), GRIK2 (rs116966225, P= 5.4 × 10− 4, − 158.5 kb and
rs78014006, P= 7.2 × 10− 3, intronic) and FAIM2 (rs297941,
P= 6.1 × 10− 5, 21.3 kb), were also identified in this meta-analysis,
although not among the top hits. Although no signal was
identified in this meta-analysis for either CDH9 or CDH10, we did
identify a strong signal for a related cadherin gene CDH20
(rs77885126, P= 4.4 × 10− 6, OR = 1.83). It should be noted that
according to a power analysis, the sample had low power to
detect genome-wide significant association with a common SNP
conferring an OR of ⩽ 1.2. The OCS GWAS was omitted from this
study because it employed a different phenotype; that is, it used a
self-report assessment tool that measured the presence of
symptoms and not the diagnosis of OCD, as opposed to a clinical
assessment that was based on OCD diagnostic criteria. We
omitted it because of these differences in phenotypes, and the
desire to not introduce additional heterogeneity into the study.
The OCS GWAS identified RFXANK as a top signal; it was also
identified among the top SNPs of this meta-analysis (rs11666960,
P= 6.3 × 10− 4, OR = 0.87).
Overall, the results from this meta-analysis support some of the
preexisting findings generated from two previous GWASs of OCD.
Among the best findings in this study are several glutamatergic
system genes (that is, GRID2, DLGAP1). Evidence has implicated
abnormalities in this system as part of the etiology of OCD and the
most robust candidate gene study results have consistently
identified genes involved in this neurotransmitter system
(GRIN2B49 and SLC1A1 (ref. 50)). Therefore, further dissection of
glutamatergic system genes along with increasing sample sizes
will improve our understanding of the underlying mechanism
of OCD.
As sample sizes grow and sequencing costs reduce further, we
anticipate that genetic associations with OCD will become
increasingly robust, and that a proportion of these currently
suggestive findings will reach genome-wide significance.
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